Skip to main content

Advertisement

SpringerLink
Log in

Androgen receptor and metastasis-associated protein-1 are frequently expressed in estrogen receptor negative/HER2 positive breast cancer

  • Original Article
  • Published:
Virchows Archiv Aims and scope Submit manuscript

Abstract

The prognostic value of androgen receptor (AR) and its related molecules in breast cancer is not well characterized. We retrospectively investigated 120 ER+ and 120 ER− invasive breast cancers of 240 women, who were treated at our institution between January 2008 and December 2009. We excluded in situ, recurrent, metastatic, and bilateral carcinomas as well as non-epithelial lesions. Median follow-up was 74 months. Immunohistochemical assessment of expression of AR and metastasis-associated protein-1 (MTA1) resulted in 59.2 % (n = 142) AR+ and 36.7 % (n = 88) high MTA1 expressing (MTA1High) carcinomas. MTA1High tumors were significantly more often ER−, while AR+ tumors were significantly more often HER2+ (p < 0.01). MTA1High/ER− tumors were more often AR−/HER2− (p < 0.01). Patients with an AR+/ER+ tumor had better disease-free survival (DFS; p = 0.011). Patients with an ER−/MTA1High tumor had significantly shorter DFS (p = 0.006) as well as patients with an AR+/HER2+ tumor (p < 0.01). In Cox models, AR expression (HR, 0.248; 95 % CI, 0.086–0.716) and lymph node status (HR, 6.401; 95 % CI, 1.428–28.686) were independent predictors for DFS in ER+ cancers, whereas AR+/HER2+ expression status (HR, 2.927; 95 % CI, 1.256–6.821) and lymph node status (HR, 2.690; 95 % CI, 1.041–7.840) were independent predictors for DFS in ER− cancers. We show that AR might be an additional marker for endocrine responsiveness in ER+ cancers and suggests that blocking MTA1 might be an effective way to inhibit AR/HER2 signaling in ER− breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Ni M, Chen Y, Lim E, Wimberly H, Bailey Shannon T, Imai Y, Rimm David L, Shirley Liu X, Brown M (2011) Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell 20(1):119–131. doi:10.1016/j.ccr.2011.05.026

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Dowsett M, Dunbier AK (2008) Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin Cancer Res 14(24):8019–8026. doi:10.1158/1078-0432.CCR-08-0974

    Article  CAS  PubMed  Google Scholar 

  3. Micello D, Marando A, Sahnane N, Riva C, Capella C, Sessa F (2010) Androgen receptor is frequently expressed in HER2-positive, ER/PR-negative breast cancers. Virchows Arch 457(4):467–476. doi:10.1007/s00428-010-0964-y

    Article  CAS  PubMed  Google Scholar 

  4. Moinfar F, Okcu M, Tsybrovskyy O, Regitnig P, Lax SF, Weybora W, Ratschek M, Tavassoli FA, Denk H (2003) Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies. Cancer 98(4):703–711. doi:10.1002/cncr.11532

    Article  CAS  PubMed  Google Scholar 

  5. Niemeier LA, Dabbs DJ, Beriwal S, Striebel JM, Bhargava R (2010) Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol 23(2):205–212. doi:10.1038/modpathol.2009.159

    Article  CAS  PubMed  Google Scholar 

  6. Ogawa Y, Hai E, Matsumoto K, Ikeda K, Tokunaga S, Nagahara H, Sakurai K, Inoue T, Nishiguchi Y (2008) Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers. Int J Clin Oncol 13(5):431–435. doi:10.1007/s10147-008-0770-6

    Article  CAS  PubMed  Google Scholar 

  7. Lawton TJ, Hawes SE, Linden H, Swanson PE, Agoff SN (2003) Androgen receptor expression in estrogen receptor-negative breast cancer immunohistochemical, clinical, and prognostic associations. Am J Clin Pathol 120(5):725–731. doi:10.1309/42f00d0djd0j5edt

    Article  PubMed  Google Scholar 

  8. Chia KM, Liu J, Francis GD, Naderi A (2011) A feedback loop between androgen receptor and ERK signaling in estrogen receptor-negative breast cancer. Neoplasia 13(2):154–166. doi:10.1593/neo.101324

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Millard CJ, Fairall L, Schwabe JW (2014) Towards an understanding of the structure and function of MTA1. Cancer Metastasis Rev 33(4):857–867. doi:10.1007/s10555-014-9513-5

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Li DQ, Pakala SB, Nair SS, Eswaran J, Kumar R (2012) Metastasis-associated protein 1/nucleosome remodeling and histone deacetylase complex in cancer. Cancer Res 72(2):387–394. doi:10.1158/0008-5472.CAN-11-2345

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Toh Y, Nicolson GL (2009) The role of the MTA family and their encoded proteins in human cancers: molecular functions and clinical implications. Clin Exp Metastasis 26(3):215–227. doi:10.1007/s10585-008-9233-8

    Article  CAS  PubMed  Google Scholar 

  12. Sen N, Gui B, Kumar R (2014) Physiological functions of MTA family of proteins. Cancer Metastasis Rev 33(4):869–877. doi:10.1007/s10555-014-9514-4

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Jang KS, Paik SS, Chung H, Oh YH, Kong G (2006) MTA1 overexpression correlates significantly with tumor grade and angiogenesis in human breast cancers. Cancer Sci 97(5):374–379. doi:10.1111/j.1349-7006.2006.00186.x

    Article  CAS  PubMed  Google Scholar 

  14. Wang RA (2014) MTA1—a stress response protein: a master regulator of gene expression and cancer cell behavior. Cancer Metastasis Rev 33(4):1001–1009. doi:10.1007/s10555-014-9525-1

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Bagheri-Yarmand R, Talukder AH, Wang RA, Vadlamudi RK, Kumar R (2004) Metastasis-associated protein 1 deregulation causes inappropriate mammary gland development and tumorigenesis. Development 131(14):3469–3479. doi:10.1242/dev.01213

    Article  CAS  PubMed  Google Scholar 

  16. Pakala SB, Rayala SK, Wang RA, Ohshiro K, Mudvari P, Reddy SD, Zheng Y, Pires R, Casimiro S, Pillai MR, Costa L, Kumar R (2013) MTA1 promotes STAT3 transcription and pulmonary metastasis in breast cancer. Cancer Res 73(12):3761–3770. doi:10.1158/0008-5472.CAN-12-3998

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Mazumdar A, Wang RA, Mishra SK, Adam L, Bagheri-Yarmand R, Mandal M, Vadlamudi RK, Kumar R (2001) Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor. Nat Cell Biol 3(1):30–37. doi:10.1038/35050532

    Article  CAS  PubMed  Google Scholar 

  18. Sobin LH, Gospodarowicz MK, Wittekind C (2009) TNM classification of malignant tumours, 7th edn. Wiley, Chichester

    Google Scholar 

  19. Edge SB, Byrd DR, Compton CC, et al. (eds) (2010) AJCC cancer staging handbook, 7th edn. Springer, New York

    Google Scholar 

  20. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19(5):403–410

    Article  CAS  PubMed  Google Scholar 

  21. Pathologists’ Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer (2010) Breast Care (Basel) 5(3):185–187

    Article  Google Scholar 

  22. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF, American Society of Clinical O, College of American P (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31(31):3997–4013. doi:10.1200/JCO.2013.50.9984

    Article  PubMed  Google Scholar 

  23. Park S, Koo JS, Kim MS, Park HS, Lee JS, Lee JS, Kim SI, Park BW, Lee KS (2011) Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers. Ann Oncol 22(8):1755–1762. doi:10.1093/annonc/mdq678

    Article  CAS  PubMed  Google Scholar 

  24. Nicolás Díaz-Chico B, Germán Rodríguez F, González A, Ramírez R, Bilbao C, Cabrera de León A, Aguirre Jaime A, Chirino R, Navarro D, Díaz-Chico JC (2007) Androgens and androgen receptors in breast cancer. J Steroid Biochem Mol Biol 105(1–5):1–15. doi:10.1016/j.jsbmb.2006.11.019

    Article  PubMed  Google Scholar 

  25. Higgins MJ, Wolff AC (2010) The androgen receptor in breast cancer: learning from the past. Breast Cancer Res Treat 124(3):619–621. doi:10.1007/s10549-010-0864-5

    Article  PubMed  Google Scholar 

  26. Naderi A, Hughes-Davies L (2008) A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer. Neoplasia 10(6):542–548. doi:10.1593/neo.08274

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Cheng CW, Liu YF, Yu JC, Wang HW, Ding SL, Hsiung CN, Hsu HM, Shieh JC, Wu PE, Shen CY (2012) Prognostic significance of cyclin D1, beta-catenin, and MTA1 in patients with invasive ductal carcinoma of the breast. Ann Surg Oncol 19(13):4129–4139. doi:10.1245/s10434-012-2541-x

    Article  PubMed  Google Scholar 

  28. Sharma G, Mirza S, Parshad R, Srivastava A, Gupta SD, Pandya P, Ralhan R (2010) Clinical significance of Maspin promoter methylation and loss of its protein expression in invasive ductal breast carcinoma: correlation with VEGF-A and MTA1 expression. Tumor Biol 32(1):23–32. doi:10.1007/s13277-010-0087-8

    Article  Google Scholar 

  29. Martin MD, Hilsenbeck SG, Mohsin SK, Hopp TA, Clark GM, Osborne CK, Allred DC, O’Connell P (2006) Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies. Breast Cancer Res Treat 95(1):7–12. doi:10.1007/s10549-005-9016-8

    Article  CAS  PubMed  Google Scholar 

  30. Salot S, Gude R (2013) MTA1-mediated transcriptional repression of SMAD7 in breast cancer cell lines. Eur J Cancer 49(2):492–499. doi:10.1016/j.ejca.2012.06.019

    Article  CAS  PubMed  Google Scholar 

  31. Park S, Koo J, Park HS, Kim JH, Choi SY, Lee JH, Park BW, Lee KS (2010) Expression of androgen receptors in primary breast cancer. Ann Oncol 21(3):488–492. doi:10.1093/annonc/mdp510

    Article  CAS  PubMed  Google Scholar 

  32. Castellano I, Allia E, Accortanzo V, Vandone AM, Chiusa L, Arisio R, Durando A, Donadio M, Bussolati G, Coates AS, Viale G, Sapino A (2010) Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. Breast Cancer Res Treat 124(3):607–617. doi:10.1007/s10549-010-0761-y

    Article  CAS  PubMed  Google Scholar 

  33. Castellano I, Chiusa L, Vandone AM, Beatrice S, Goia M, Donadio M, Arisio R, Muscara F, Durando A, Viale G, Cassoni P, Sapino A (2013) A simple and reproducible prognostic index in luminal ER-positive breast cancers. Ann Oncol 24(9):2292–2297. doi:10.1093/annonc/mdt183

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Macedo LF, Guo Z, Tilghman SL, Sabnis GJ, Qiu Y, Brodie A (2006) Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole. Cancer Res 66(15):7775–7782. doi:10.1158/0008-5472.CAN-05-3984

    Article  CAS  PubMed  Google Scholar 

  35. Peters AA, Buchanan G, Ricciardelli C, Bianco-Miotto T, Centenera MM, Harris JM, Jindal S, Segara D, Jia L, Moore NL, Henshall SM, Birrell SN, Coetzee GA, Sutherland RL, Butler LM, Tilley WD (2009) Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res 69(15):6131–6140. doi:10.1158/0008-5472.CAN-09-0452

    Article  CAS  PubMed  Google Scholar 

  36. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, Macgrogan G, Bergh J, Cameron D, Goldstein D, Duss S, Nicoulaz AL, Brisken C, Fiche M, Delorenzi M, Iggo R (2005) Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 24(29):4660–4671. doi:10.1038/sj.onc.1208561

    Article  CAS  PubMed  Google Scholar 

  37. Doane AS, Danso M, Lal P, Donaton M, Zhang L, Hudis C, Gerald WL (2006) An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 25(28):3994–4008. doi:10.1038/sj.onc.1209415

    Article  CAS  PubMed  Google Scholar 

  38. Lehmann-Che J, Hamy AS, Porcher R, Barritault M, Bouhidel F, Habuellelah H, Leman-Detours S, de Roquancourt A, Cahen-Doidy L, Bourstyn E, de Cremoux P, de Bazelaire C, Albiter M, Giacchetti S, Cuvier C, Janin A, Espie M, de The H, Bertheau P (2013) Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15. Breast Cancer Res 15(3):R37. doi:10.1186/bcr3421

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

This work was financially supported by National Natural Science Foundation of China (81172532).

Author information

Authors and Affiliations

  1. Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, West Huanhu Road, Ti Yuan Bei, Hexi District, Tianjin, 300060, China

    Lin Zhao, Fengting Niu, Honghong Shen, Xiaozhen Liu, Lijuan Chen & Yun Niu

Authors
  1. Lin Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fengting Niu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Honghong Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiaozhen Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lijuan Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yun Niu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yun Niu.

Ethics declarations

This study was approved by the Tianjin Medical University Cancer Institute and Hospital, China, and has been performed in accordance with the ethical standards laid down in the 1964 Helsinki Declaration and its later amendments.

Funding

This study was funded by National Natural Science Foundation of China (grant number 81172532).

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhao, L., Niu, F., Shen, H. et al. Androgen receptor and metastasis-associated protein-1 are frequently expressed in estrogen receptor negative/HER2 positive breast cancer. Virchows Arch 468, 687–696 (2016). https://doi.org/10.1007/s00428-016-1930-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00428-016-1930-0

Keywords

Search

Navigation